|
|
- Ronald Johnson
- 6 years ago
- Views:
Transcription
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 References: 1. XVI International AIDS Conference, 2006 Abstract no. ThPE Bergshoeff A, Burger D, Farrelly L e t al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-Infected Children: PENTA th Conference on Retroviruses and Opportunistic Infections, Poster number Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection October 26, 2006 Page 29 Supplement I: Pediatric Antiretroviral Drug Information 4. PENTA guidelines. HIV Medicine 2004: 5: AIDS 2003; 17: AIDS 2008, 22: Lancet 364, (2004). 8. NACO guidelines for HIV care and treatment in infants and children, November Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access: WHO
29 Appendix 1 Estimation of Body Surface Area in Infants and Children* Weight (kg) Surface area (m 2 ) Weight (kg) Surface area (m 2 ) Weight (kg) Surface area (m 2 )
30
31 Caution (for children less than 10 kg body weight) For children < 10 kg body weight, dosing by body surface area represents a change in usual clinical practice, this will result in an increase in calculated dose. The implications of this change in clinical practice are not known in terms of drug toxicity. Recommendations: Starting doses: For infants < 6 months of age: 50% of calculated dose by body surface area. For infants 6 months 1 year of age: 75% of calculated dose by body surface area For infants over 1 year of age: 100% of calculated dose by body surface area These doses may be adjusted according to clinical circumstances Individual investigators (protocols) should have clear recommendations for dosing in infants *From the United Kingdom Children s Cancer Study Group (UKCCSG) Chemotherapy Standardisation Group. 71
32 Appendix 2 Weight band Equivalent BSA for each weight band a Recommended dose (mg) range using 300mg/m 2b Recommended dose (mg) range using 400mg/m 2b Actual nevirapine dose (mg) 3-< < < < < < a From the UKCCSG (Appendix 1) b PENTA Guidelines recommend dosing at mg/m 2 for children aged 1 month to Tanner stage 3 72
33 Appendix 3 Dosing recommendations for chronic treatment of children are somewhat controversial. Body surface area has traditionally been used to guide NVP dosing for infants and young children, with dosing recommended at 120 to 200 mg per meter 2 of body surface area every 12 hours, at a maximum of 200 mg per dose. Younger children (e.g., age < 8 years) may require the higher range of dosage (i.e., 200 mg per meter 2 of body surface area twice daily) [17, 19]. The drug label also includes dosing recommendations based on mg/kg dosing, with 7 mg/kg every 12 hours recommended for children aged < 8 years and 4 mg/kg every 12 hours recommended for children aged > 8 years, with a maximum dose of 200 mg. NVP apparent clearance adjusted for body weight is approximately two-fold greater in children under age 8 years; however, these clearance changes are gradual and the mg/kg dosing recommendations result in an abrupt 43% decrease in dose size when the 8 th birthday is reached. Thus, many clinicians prefer the mg per meter 2 of body surface area dosing that was used in clinical trials, particularly for children around the eighth birthday. Ref: Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection October 26, 2006 Page 29 Supplement I: Pediatric Antiretroviral Drug Information 73
34 Appendix 4 74
35 Ref: HIV Medicine 2004: 5: Appendix 5 Superior virologic responses with higher nevirapine doses Verweel et al studied the safety and clinical, virological and immunological responses in 74 HIV- 1-infected children 96 weeks after starting a nevirapine-containing regimen. Nevirapine was dosed at the discretion of the paediatrician, according to the manufacturer s guidelines (an initial dose of 120 mg/m 2 /day, increased if no rash occurred after 2 weeks to a maintenance dose of 300 mg/m 2 /day for children < 8 years and 240 mg/m 2 /day for children > 8 years. Children were categorized into high, recommended or low dosage. If the dose was greater than 300 mg/m 2 /day before week 24 they were classified as high. If at all timepoints the dose was less than 240 mg/m 2 /day they were classified as low. The rest were classified as recommended. The median age was 5.2 years and median baseline viral load was 5.1 log copies/ml. In children using nevirapine and NRTI who were maintained on a high (> 300 mg/m 2 per day) dosage of nevirapine, significantly more patients had an undetectable viral load at weeks 24 (P = 0.012) and 96 (P = 0.007) compared with patients on recommended dosages ( mg/m 2 per day; P = and P = 0.007, respectively) and compared with patients on lower dosages (< 240 mg/m 2 per day; P = and P = 0.007, respectively). At week 48 a trend towards more patients with an undetectable viral load was seen for patients receiving a high dosage of nevirapine compared with patients on recommended (P = 0.066) or lower (P = 0.071) dosages. If the dosage was increased for children on a recommended or lower dosages to more than 300 mg/m 2 per day when the viral load was already undetectable, the viral load continued to be undetectable up to at least week 96. When the viral load was not undetectable or rebounded, three out of four patients reached undetectable levels if the dosage was increased before 24 weeks of treatment. 75
36 Proportion of patients with undetectable viral load (%) w eeks 24 w eeks 48 w eeks 96 w eeks Time after Nevirapine initiation in w eeks low dosage recommended dosage high dosage Figure: Proportion of patients achieving undetectable viral load levels (< 400 copes/ml) on high (> 300 mg/m 2 /day), recommended ( mg/m 2 /day) and low (< 240 mg/m 2 /day) dosage of nevirapine, intention-to-treat analysis, missing equals failure, last value carried forward. Ref: AIDS 2003; 17:
Pediatric Patient Information:
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral
More informationPediatric ARV Working Group Dosing Recommendations
Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationCCC ARV Dosing Recommendations for HIV-exposed infants Updated
USERS NOTE: Please note this document does not provide guidance on overall decisionmaking regarding what medication(s) to use for HIV-exposed infants. This document is meant to facilitate ARV dosing for
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationSafety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationThe Genetic Barrier to Resistance
The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013 The Genetic Barrier to Resistance The genetic
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationAWMSG Secretariat Assessment Report Advice no Darunavir (Prezista
AWMSG Secretariat Assessment Report Advice no. 0311 Darunavir (Prezista ) for the treatment of HIV-1 infection in treatment-experienced children and adolescents This assessment report is based on evidence
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationEFFECT OF FIRST LINE THERAPY INCLUDING EFAVIRENZ AND TWO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS IN HIV-INFECTED CHILDREN
December 7, 2005 EUROPEAN JOURNAL OF MEDICAL RESEARCH 503 Eur J Med Res (2005) 10: 503-508 I. Holzapfel Publishers 2005 EFFECT OF FIRST LINE THERAPY INCLUDING EFAVIRENZ AND TWO NUCLEOSIDE REVERSE TRANSCRIPTASE
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationDepartment of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands 6
Antiviral Therapy 2010 15:343 350 (doi: 10.3851/IMP1544) Original article Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPediatric Antiretroviral Therapy
Update on Pediatric Antiretroviral Therapy Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationWARNING LETTER. ( (last accessed July 10, 2009).
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Miles D. White Chairman of the Board & Chief Executive Officer
More informationPlasma pharmacokinetics of once-daily abacavir- and lamivudinecontaining regimens and week 96 efficacy in HIV-infected Thai children
Plasma pharmacokinetics of once-daily abacavir- and lamivudinecontaining regimens and week 96 efficacy in HIV-infected Thai children Torsak Bunupuradah 1, Passorn Punyahotra 2, Tim R Cressey 3,4, Amornrat
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationINTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY
PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO
More informationPAEDIATRIC ANTIRETROVIRAL THERAPY FOR THE GENERAL PRACTITIONER
PAEDIATRIC ANTIRETROVIRAL THERAPY FOR THE GENERAL PRACTITIONER The care of HIV-infected children is somewhat different to that of adults, and although this poses some challenges, it should not impede paediatric
More information1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London
A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationRecommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationJOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN
JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim
More informationHIV and FDC aspects of two guidelines. Filip Josephson
HIV and FDC aspects of two guidelines Filip Josephson Status Ongoing process Updated draft guideline for HIV drug development available for public consultation on EMA website since 2013 Presently under
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationPerinatal HIV Exposure: Antiretroviral Management. Danielle McDonald, PharmD PGY-2 Pediatric Pharmacotherapy Resident
Perinatal HIV Exposure: Antiretroviral Management Danielle McDonald, PharmD PGY-2 Pediatric Pharmacotherapy Resident A presentation for HealthTrust Members June 1, 2018 Learning Objectives for Pharmacists
More informationPublic Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir
Public Assessment Report EU worksharing project paediatric data Valcyte Valganciclovir Currently approved indication(s): Pharmaceutical form(s) affected by this project: Strength(s) affected by this variation:
More informationModule 6: ARVs in Children
Module 6: ARVs in Children Module Objectives To review the use of ARVs in children and their impact on disease progression To provide nurses with a general understanding of the differences in ARV use in
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPractical Scenarios Calculating doses for newborns. Karen Buckberry
Practical Scenarios Calculating doses for newborns Karen Buckberry Real Life Midwife phones you HIV+ mother in labour Needs you to tell Dr what meds to prescribe for baby What info do you need? Info needed
More informationPaediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff
Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme- 20171031[2].tiff Mo Archary King Edward VIII Hospital / UKZN Paediatric Infectious Diseases Unit Overview State
More informationVirologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study.
Virologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study. K. Reichmuth 1, J. Nuttall, H. Rabie, B. Eley, H. Moultrie,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationAntiviral for systemic use. Darunavir is an inhibitor of Human Immunodeficiency Virus type 1 (HIV-1) protease.
PREZISTA DATA SHEET NAME OF THE DRUG Darunavir DESCRIPTION Antiviral for systemic use. Darunavir is an inhibitor of Human Immunodeficiency Virus type 1 (HIV-1) protease. PREZISTA darunavir is available
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationBaylor-Uganda, Paediatric Infectious Diseases Clinic, Mulago Hospital, Kampala, Uganda 4
Antiviral Therapy 2010; 15:1115 1124 (doi: 10.3851/IMP1695) Original article Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1- infected Ugandan children
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationJames Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital
James Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital Paediatric HIV Infection Symposium, August 21, 2010, Red Cross Children s Hospital Overview of talk The 2010 paediatric guidelines
More informationProtease inhibitors (PIs) for human immunodeficiency
Nelfinavir Pharmacokinetics in Stable Human Immunodeficiency Virus- Positive Children: Pediatric AIDS Clinical Trials Group Protocol 377 Leslie Carstensen Floren, PharmD*; Andrew Wiznia, MD ; Sandra Hayashi,
More informationNevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia
Antiviral Therapy 12:253 260 Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia Jane C Ellis 1, Rafaëlla FA L homme
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 30 Dec 2018 00:34:16 GMT) CTRI Number CTRI/2009/091/000652 [Registered on: 27/10/2009] - Last Modified On 11/03/2014 Post Graduate Thesis Type of Trial
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationRedefining The Math. The less the better WEEKS. Daclatasvir 60 mg Tablet K S
Redefining The Math 12 24 WEEKS W EE K S Hepatitis C; the most notorious of all hepatitis infections, has becoming a world threat due to its high morbidity and mortality rate. Moreover, with the prevalence
More informationDownloaded from:
Dakshina, S; Olaru, I; Khan, P; Raman, L; McHugh, G; Bwakura, M; Nathoo, K; Munyati, S; Mujuru, H; Ferrand, Rashida (2019) Evaluation of weight-based prescription of antiretroviral therapy in children.
More information3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationThe NEW ARV Guidelines FAQs
The NEW ARV Guidelines FAQs Dr Madeleine Muller MBChB (Pret).MRCGP(Lon).Dip Hiv Man IYDSA Clinical Advisor Acknowledgments IYDSA for materials and support NDOH for slides CDC our funder HIV Clinician Society
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationDr Melanie Rosenvinge
18 th Annual Conference of the British HIV Association (BHIVA) Dr Melanie Rosenvinge St George s Hospital NHS Trust, London 1820 April 2012, The International Convention Centre, Birmingham A multicentre
More informationTitle: What ARV regimen to start in children 3 years old? (TDF)
Title: What ARV regimen to start in children 3 years old? (TDF) Contents 1. PICO question... 1 2. Search strategy... 1 3. Flow diagram of screening process... 2 4. Evidence summaries... 2 5. Bibliography
More informationClinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages) NHS England Reference: B06/P/a
Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages) NHS England Reference: B06/P/a 1 2 Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all
More informationCalculations. Doses and Dosage Regimens. Pharmacy Technician Training Systems Passassured, LLC
Calculations Doses and Dosage Regimens Pharmacy Technician Training Systems Passassured, LLC Calculations, Doses and Dosage Regimens Calculations, Doses and Dosage Regimens Objectives Expressions of Dose
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informations. Ghosh 1 *, J. neubert 1 *, t. niehues 2, o. adams 3, n. Morali-Karzei 1, a. Borkhardt 1, H. J. laws 1
June 21, 2011 Eu Ro PE an JouR nal of MEd I cal RE search 243 Eur J Med Res (2011) 16: 243-248 I. Holzapfel Publishers 2011 InductIon MaIntEnancE concept for HaaRt as InItIal treatment In HIV InfEctEd
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationOnce-a-Day Highly Active Antiretroviral Therapy: A Systematic Review
HIV/AIDS MAJOR ARTICLE Once-a-Day Highly Active Antiretroviral Therapy: A Systematic Review Javier Ena and Francisco Pasquau HIV Unit, Department of Internal Medicine, Marina Baixa Hospital, Villajoyosa,
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Epivir 150
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationKanapathipillai, Rupa; McGuire, Megan; Mogha, Robert; Szumilin, Elisabeth; Heinzelmann, Annette; Pujades- Rodriguez, Mar
MSF Field Research Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi. Authors Citation DOI Journal Rights Kanapathipillai, Rupa; McGuire, Megan;
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationSafety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients
Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients Amy Moore, Sonali Sonecha, Tristan Barber, Anton Pozniak, David Asboe, Marta Boffito
More information7th International Workshop on Clinical Pharmacology of HIV Therapy Lisbon,, Portugal April 20-22, 22, 2006
7th International Workshop on Clinical Pharmacology of HIV Therapy Lisbon,, Portugal April 20-22, 22, 2006 Nancy Sheehan, B.Pharm, M.Sc Immunodeficiency Service, Montréal Chest Institute Faculté de Pharmacie,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationTransient viral load increases in HIV-infected children in the UK and Ireland: what do they mean?
Transient viral load increases in HIV-infected children in the UK and Ireland: what do they mean? Katherine J Lee 1 *, Delane Shingadia 2, Deenan Pillay 3, A Sarah Walker 1, Andrew Riordan 4, Esse Menson
More informationANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL
ZIDOVUDINE (AZT, Retrovir ) Benefits of zidovudine: Zidovudine (ZDV) is an antiretroviral drug that slows the growth of the HIV virus. It has shown in a large randomized, multicentre study to decrease
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More information